Fellowship ​

Professor Peter Ebeling’s national and international recognition for excellence in health and medical science is demonstrated by key leadership roles at the highest level, including as first non-North American President of the American Society of Bone and Mineral Research, Past-president of the Endocrine Society of Australia and Australian and New Zealand Bone and Mineral Society, and Board Member of the International Osteoporosis Foundation. Professor Ebeling mentors PhD students and endocrinology trainees and chairs Healthy Bones Australia, through which he has raised public understanding of bone health.

Professor Ebeling’s significant, sustained and ongoing contributions to advance health and medical science have led to changes in clinical practice and health policy.

Professor Ian Davis is a medical oncologist with over 30 years’ experience and primary clinical and research focus in genitourinary cancers. He founded and chairs the ANZUP (Australian and New Zealand Urogenital and Prostate) Cancer Trials Group and is the global co-chair of international ANZUP ENZAMET trial. This trial demonstrated improved survival with enzalutamide for metastatic hormone-sensitive prostate cancer and has led to regulatory approval in US, Europe, Japan, and Australia, leading to multiple awards, including the 2020 Trial of the Year.

Through ANZUP, Professor Davis has established a global genitourinary cancer clinical trials network and mentored many senior clinician-researchers.

Professor Phillip Darcy is an NHMRC Principal Research Fellow and Group Leader at the Peter MacCallum Cancer Centre. His work has been pivotal in developing novel T cell-based immunotherapy approaches for cancer patients. In particular, his studies involving the development of technology using gene‐modified T cells expressing chimeric antigen receptors (CARs) in preclinical models has led to licensing of an international patent to industry partners and underpins five FDA/TGA‐approved therapies for CD19+ blood cancers.

Professor Darcy’s work has also been integral in the first CAR T cell trial undertaken in Australia.

Professor Leonid Churilov is a clinical biostatistician who led complex and comprehensive design and analysis of acute and recovery stroke trials that resulted in global changes in clinical practice, and are internationally recognized through multiple publications in the highest impact medical journals including NEJM, The Lancet and JAMA.

Professor Churilov led the development, and wide adoption by the Australian stroke clinical community, of novel clinical trial designs, original analytical approaches and outcome measurements from “bench-to-bedside”. His decision-modelling effort provided analytical underpinnings for acute stroke processes of care adopted both nationally and internationally, including the activities of the first Australian stroke ambulance.

Professor David Burgner is a practising paediatric infectious diseases physician, leads the Inflammatory Origins Group and co-leads the LifeCourse longitudinal observational cohorts initiative at Murdoch Children’s Research Institute. He is Education Officer for the World Society of Paediatric Infectious Diseases.

Professor Burgner is an international authority on understanding the susceptibility and consequences to childhood infection and inflammation, particularly in relation to the development of cardiometabolic disease risk. He is an internationally-recognised clinical and scientific leader in Kawasaki disease and has made major scientific, clinical and policy contributions to the Australian response to the COVID-19 pandemic, particularly the hyperinflammatory post-infectious syndrome in children.